Sannino Anna, Szerlip Molly, Harrington Katherine, Schiattarella Gabriele G, Grayburn Paul A
Baylor Heart and Vascular Hospital, Baylor University Medical Center, Dallas, Texas.
Cardiology Section, The Heart Hospital Baylor Plano, Plano, Texas.
Am J Cardiol. 2018 Apr 1;121(7):844-849. doi: 10.1016/j.amjcard.2017.12.020. Epub 2018 Jan 10.
Female gender has been linked to increased risk of adverse events after surgical aortic valve replacement; however, the evidence regarding the role of gender differences on clinical outcomes in patients who underwent transcatheter aortic valve implantation (TAVI) is still debated. This retrospective study included 910 consecutive patients with severe, symptomatic aortic stenosis who underwent TAVI in 2 institutions from January 2012 to July 2016. The primary end point was all-cause mortality at 1 year after TAVI in women versus men. Women had a higher incidence of in-hospital vascular complications (7.8% vs 4.1%) and major or life-threatening bleeding (4.0% vs 1.6%) than men. At 1 year, women showed a lower mortality rate than men (7.0% vs 12.7%, adjusted hazard ratio [HR] 0.42, 95% confidence interval [CI] [0.23 to 0.76], p = 0.004). When stratifying by specific subgroups of interest, the survival benefit in women persisted in (1) patients with a Society of Thoracic Surgery risk score ≤ 8 (adjusted HR 0.35, 95% CI [0.14 to 0.88], p = 0.026); (2) patients treated with first-generation devices (adjusted HR 0.46, 95% CI [0.24 to 0.86], p = 0.016); and (3) patients treated with balloon-expandable valves (adjusted HR 0.40, 95% CI [0.19 to 0.86], p = 0.019). In conclusion, in this large patient cohort, women had lower 1-year mortality after TAVI than men, particularly with an STS score ≤ 8, or treated with first-generation and balloon-expandable devices.
女性与外科主动脉瓣置换术后不良事件风险增加有关;然而,关于性别差异在经导管主动脉瓣植入术(TAVI)患者临床结局中的作用的证据仍存在争议。这项回顾性研究纳入了2012年1月至2016年7月在2家机构接受TAVI的910例连续的重度症状性主动脉瓣狭窄患者。主要终点是TAVI术后1年女性与男性的全因死亡率。女性住院期间血管并发症(7.8%对4.1%)和严重或危及生命的出血(4.0%对1.6%)的发生率高于男性。1年时,女性的死亡率低于男性(7.0%对12.7%,调整后风险比[HR]0.42,95%置信区间[CI][0.23至0.76],p = 0.004)。按感兴趣的特定亚组分层时,女性的生存获益在以下情况中持续存在:(1)胸外科医师学会风险评分≤8的患者(调整后HR 0.35,95% CI[0.14至0.88],p = 0.026);(2)接受第一代装置治疗的患者(调整后HR 0.46,95% CI[0.24至0.86],p = 0.016);以及(3)接受球囊扩张瓣膜治疗的患者(调整后HR 0.40,95% CI[0.19至0.86],p = 0.019)。总之,在这个大型患者队列中,TAVI术后1年女性的死亡率低于男性,特别是在胸外科医师学会评分≤8或接受第一代和球囊扩张装置治疗的患者中。